⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

モデル
薬剤
インサイト

Company

CROパートナー
Contact Us
Privacy Policy

© 2025 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Retatrutide (Retatrutide) | 加速させる、線維化研究を

Home/Drugs/Retatrutide

Retatrutide

Retatrutide

Phase 3

Sponsor: Eli Lilly

Indication: MASH / Obesity

Mechanism of Action

Triple Agonist (GLP-1/GIP/Glucagon)

Target: GLP-1Target: GIPTarget: Glucagon

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

ACTIVE_NOT_RECRUITINGNCT06859268

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

Phase:PHASE3Org:Eli Lilly and Company

RECRUITING

Relevant Publications (PubMed)

No recent publications found for Retatrutide.

Validated Models

This drug has been validated in the following preclinical models:

NCT06982859

A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus

Phase:PHASE1Org:Eli Lilly and Company

ACTIVE_NOT_RECRUITINGNCT06354660

Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

Phase:PHASE3Org:Eli Lilly and Company

ACTIVE_NOT_RECRUITINGNCT05929066

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

Phase:PHASE3Org:Eli Lilly and Company

ACTIVE_NOT_RECRUITINGNCT06297603

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

Phase:PHASE3Org:Eli Lilly and Company

View all trials on ClinicalTrials.gov